These findings bridge genetic and microenvironmental mechanisms of immune evasion and highlight MS4A6A both as a mechanistic biomarker identifying a therapeutically vulnerable TAM subpopulation and as a potential guide for rational combinations of PGE2/EP4 and ERK/mTOR-targeted therapies in GBM. This evidence concerns the gene MTOR and glioblastoma.